|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.1Cancer Incidence and Mortality Worldwide:
IARC CancerBase No. 11 (Internet). Lyon, France: International
Agency for Research on Cancer; 2014 http://globocan.iarc.frAccessed. August
10–2016
|
|
2
|
Bhat S, Kabekkodu SP, Noronha A and
Satyamoorthy K: Biological implications and therapeutic
significance of DNA methylation regulated genes in cervical cancer.
Biochimie. 121:298–311. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Banzai C, Nishino K, Quan J, Yoshihara K,
Sekine M, Yahata T and Tanaka K: Gynecological Cancer Registry of
Niigata: Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A
genes in cervical carcinoma. Int J Clin Oncol. 19:127–132. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu SS, Leung RC, Chan KY, Chiu PM, Cheung
AN, Tam KF, Ng TY, Wong LC and Ngan HY: p73 expression is
associated with the cellular radiosensitivity in cervical cancer
after radiotherapy. Clin Cancer Res. 10:3309–3316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roz L, Gramegna M, Ishii H, Croce CM and
Sozzi G: Restoration of fragile histidine triad (FHIT) expression
induces apoptosis and suppresses tumorigenicity in lung and
cervical cancer cell lines. Proc Natl Acad Sci USA. 99:3615–3320.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Snellenberg S, Cillessen SA, Van Criekinge
W, Bosch L, Meijer CJ, Snijders PJ and Steenbergen RD:
Methylation-mediated repression of PRDM14 contributes to apoptosis
evasion in HPV-positive cancers. Carcinogenesis. 35:2611–2618.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Q, Shi H, Suo Z and Nesland JM: 5′-CpG
island methylation of the FHIT gene is associated with reduced
protein expression and higher clinical stage in cervical
carcinomas. Ultrastruct Pathol. 27:417–422. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kitkumthorn N, Yanatatsanajit P,
Kiatpongsan S, Phokaew C, Triratanachat S, Trivijitsilp P,
Termrungruanglert W, Tresukosol D, Niruthisard S and Mutirangura A:
Cyclin A1 promoter hypermethylation in human
papillomavirus-associated cervical cancer. BMC Cancer. 6:552006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chujan S, Kitkumthorn N, Siriangkul S and
Mutirangura A: CCNA1 promoter methylation: A potential marker for
grading Papanicolaou smear cervical squamous intraepithelial
lesions. Asian Pac J Cancer Prev. 15:7971–7975. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kabekkodu SP, Bhat S, Radhakrishnan R,
Aithal A, Mascarenhas R, Pandey D, Rai L, Kushtagi P, Mundyat GP
and Satyamoorthy K: DNA promoter methylation-dependent
transcription of the double C2-like domain β (DOC2B) gene regulates
tumor growth in human cervical cancer. J Biol Chem.
289:10637–10649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aoki K and Taketo MM: Adenomatous
polyposis coli (APC): A multi-functional tumor suppressor gene. J
Cell Sci. 120:3327–3335. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin YW, Chung MT, Lai HC, De Yan M, Shih
YL, Chang CC and Yu MH: Methylation analysis of SFRP genes family
in cervical adenocarcinoma. J Cancer Res Clin Oncol. 135:1665–1674.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Narayan G, Arias-Pulido H, Nandula SV,
Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer
L, Schneider A, et al: Promoter hypermethylation of FANCF:
Disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
Cancer Res. 64:2994–2997. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Henken FE, Wilting SM, Overmeer RM, van
Rietschoten JG, Nygren AO, Errami A, Schouten JP, Meijer CJ,
Snijders PJ and Steenbergen RD: Sequential gene promoter
methylation during HPV-induced cervical carcinogenesis. Br J
Cancer. 97:1457–1464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Virmani AK, Muller C, Rathi A,
Zoechbauer-Mueller S, Mathis M and Gazdar AF: Aberrant methylation
during cervical carcinogenesis. Clin Cancer Res. 7:584–589.
2001.PubMed/NCBI
|
|
16
|
Bai LX, Wang JT, Ding L, Jiang SW, Kang
HJ, Gao CF, Chen X, Chen C and Zhou Q: Folate deficiency and FHIT
hypermethylation and HPV 16 infection promote cervical
cancerization. Asian Pac J Cancer Prev. 15:9313–9317. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ivanova T, Petrenko A, Gritsko T,
Vinokourova S, Eshilev E, Kobzeva V, Kisseljov F and Kisseljova N:
Methylation and silencing of the retinoic acid receptor-beta 2 gene
in cervical cancer. BMC Cancer. 2:42002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Strooper LM, van Zummeren M,
Steenbergen RD, Bleeker MC, Hesselink AT, Wisman GB, Snijders PJ,
Heideman DA and Meijer CJ: CADM1, MAL and miR124-2 methylation
analysis in cervical scrapes to detect cervical and endometrial
cancer. J Clin Pathol. 67:1067–1071. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JH, Choi YD, Lee JS, Lee JH, Nam JH
and Choi C: Assessment of DNA methylation for the detection of
cervical neoplasia in liquid-based cytology specimens. Gynecol
Oncol. 116:99–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yadav SS, Prasad SB, Das M, Kumari S,
Pandey LK, Singh S, Pradhan S and Narayan G: Epigenetic silencing
of CXCR4 promotes loss of cell adhesion in cervical cancer. Biomed
Res Int. 2014:5814032014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Overmeer RM, Henken FE, Snijders PJ,
Claassen-Kramer D, Berkhof J, Helmerhorst TJ, Heideman DA, Wilting
SM, Murakami Y, Ito A, et al: Association between dense CADM1
promoter methylation and reduced protein expression in high-grade
CIN and cervical SCC. J Pathol. 215:388–397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bischoff J, Ignatov A, Semczuk A,
Schwarzenau C, Ignatov T, Krebs T, Küster D, Przadka-Rabaniuk D,
Roessner A, Costa SD and Schneider-Stock R: hMLH1 promoter
hypermethylation and MSI status in human endometrial carcinomas
with and without metastases. Clin Exp Metastasis. 29:889–900. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guida M, Sanguedolce F, Bufo P, Di Spiezio
Sardo A, Bifulco G, Nappi C and Pannone G: Aberrant DNA
hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign,
premalignant and malignant endometrial lesions. Eur J Gynaecol
Oncol. 30:267–270. 2009.PubMed/NCBI
|
|
24
|
Pallarés J, Velasco A, Eritja N, Santacana
M, Dolcet X, Cuatrecasas M, Palomar-Asenjo V, Catasús L, Prat J and
Matias-Guiu X: Promoter hypermethylation and reduced expression of
RASSF1A are frequent molecular alterations of endometrial
carcinoma. Mod Pathol. 21:691–699. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Banno K, Yanokura M, Susumu N, Kawaguchi
M, Hirao N, Hirasawa A, Tsukazaki K and Aoki D: Relationship of the
aberrant DNA hypermethylation of cancer-related genes with
carcinogenesis of endometrial cancer. Oncol Rep. 16:1189–1196.
2006.PubMed/NCBI
|
|
26
|
Jo H, Kim JW, Kang GH, Park NH, Song YS,
Kang SB and Lee HP: Association of promoter hypermethylation of the
RASSF1A gene with prognostic parameters in endometrial cancer.
Oncol Res. 16:205–209. 2006.PubMed/NCBI
|
|
27
|
Lee KE: Immunohistochemical assessment of
O(6)-methylguanine-DNA methyltransferase (MGMT) and Its
relationship with p53 expression in endometrial cancers. J Cancer
Prev. 18:351–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ignatov A, Bischoff J, Ignatov T,
Schwarzenau C, Krebs T, Kuester D, Costa SD, Roessner A, Semczuk A
and Schneider-Stock R: APC promoter hypermethylation is an early
event in endometrial tumorigenesis. Cancer Sci. 101:321–327. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suehiro Y, Okada T, Okada T, Anno K,
Okayama N, Ueno K, Hiura M, Nakamura M, Kondo T, Oga A, et al:
Aneuploidy predicts outcome in patients with endometrial carcinoma
and is related to lack of CDH13 hypermethylation. Clin Cancer Res.
14:3354–3361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fiolka R, Zubor P, Janusicova V, Visnovsky
J, Mendelova A, Kajo K, Lasabova Z, Plank L and Danko J: Promoter
hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and
CDH1 in endometrial cancer. Oncol Rep. 30:2878–2886.
2013.PubMed/NCBI
|
|
31
|
Park JH, Lee BI, Song ES, Whang SO, Lee WY
and Cho SJ: Hypermethylation of E-cadherin in endometrial
carcinoma. J Gynecol Oncol. 19:241–245. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saito T, Nishimura M, Yamasaki H and Kudo
R: Hypermethylation in promoter region of E-cadherin gene is
associated with tumor dedifferention and myometrial invasion in
endometrial carcinoma. Cancer. 97:1002–1009. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan
HY: Differential DNA methylation profiles in gynecological cancers
and correlation with clinico-pathological data. BMC Cancer.
6:2122006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kang S, Lee JM, Jeon ES, Lee S, Kim H, Kim
HS, Seo SS, Park SY, Sidransky D and Dong SM: RASSF1A
hypermethylation and its inverse correlation with BRAF and/or KRAS
mutations in MSI-associated endometrial carcinoma. Int J Cancer.
119:1316–1321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sánchez-Vega F, Gotea V, Petrykowska HM,
Margolin G, Krivak TC, DeLoia JA, Bell DW and Elnitski L: Recurrent
patterns of DNA methylation in the ZNF154, CASP8 and VHL promoters
across a wide spectrum of human solid epithelial tumors and cancer
cell lines. Epigenetics. 8:1355–1372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chan QK, Khoo US, Chan KY, Ngan HY, Li SS,
Chiu PM, Man LS, Ip PP, Xue WC and Cheung AN: Promoter methylation
and differential expression of pi-class glutathione S-transferase
in endometrial carcinoma. J Mol Diagn. 7:8–16. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Moreno-Bueno G, Fernandez-Marcos PJ,
Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I,
Hardisson D, Diaz-Meco MT, Moscat J, Serrano M and Palacios J:
Inactivation of the candidate tumor suppressor par-4 in endometrial
cancer. Cancer Res. 67:1927–1934. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wong OG, Huo Z, Siu MK, Zhang H, Jiang L,
Wong ES and Cheung AN: Hypermethylation of SOX2 promoter in
endometrial carcinogenesis. Obstet Gynecol Int.
2010:pii:6825042010. View Article : Google Scholar
|
|
39
|
Muraki Y, Banno K, Yanokura M, Kobayashi
Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N and Aoki D:
Epigenetic DNA hypermethylation: Clinical applications in
endometrial cancer (Review). Oncol Rep. 22:967–972. 2009.PubMed/NCBI
|
|
40
|
Zhang QY, Yi DQ, Zhou L, Zhang DH and Zhou
TM: Status and significance of CpG island methylator phenotype in
endometrial cancer. Gynecol Obstet Invest. 72:183–191. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Semczuk A, Boltze C, Marzec B,
Szczygielska A, Roessner A and Schneider-Stock R: p16INK4A
alterations are accompanied by aberrant protein immunostaining in
endometrial carcinomas. J Cancer Res Clin Oncol. 129:589–596. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sasaki M, Oh BR, Dharia A, Fujimoto S and
Dahiya R: Inactivation of the human androgen receptor gene is
associated with CpG hypermethylation in uterine endometrial cancer.
Mol Carcinog. 29:59–66. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sasaki M, Dharia A, Oh BR, Tanaka Y,
Fujimoto S and Dahiya R: Progesterone receptor B gene inactivation
and CpG hypermethylation in human uterine endometrial cancer.
Cancer Res. 61:97–102. 2001.PubMed/NCBI
|
|
44
|
Li R, Saito T, Tanaka R, Satohisa S,
Adachi K, Horie M, Akashi Y and Kudo R: Hypermethylation in
promoter region of retinoic acid receptor-beta gene and
immunohistochemical findings on retinoic acid receptors in
carcinogenesis of endometrium. Cancer Lett. 219:33–40. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dong R, Pu H, Wang Y, Yu J, Lian K and Mao
C: TESTIN was commonly hypermethylated and involved in the
epithelial-mesenchymal transition of endometrial cancer. APMIS.
123:394–400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chmelarova M, Kos S, Dvorakova E, Spacek
J, Laco J, Ruszova E, Hrochova K and Palicka V: Importance of
promoter methylation of GATA4 and TP53 genes in endometrioid
carcinoma of endometrium. Clin Chem Lab Med. 52:1229–1234. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Catasus L, Pons C, Muñoz J, Espinosa I and
Prat J: Promoter hypermethylation contributes to TIMP3
down-regulation in high stage endometrioid endometrial carcinomas.
Histopathology. 62:632–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Boers A, Wang R, van Leeuwen RW, Klip HG,
de Bock GH, Hollema H, van Criekinge W, de Meyer T, Denil S, van
der Zee AGJ, et al: Discovery of new methylation markers to improve
screening for cervical intraepithelial neoplasia grade 2/3. Clin
Epigenetics. 8:292016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang LY, Han CS, Li PL and Zhang XC:
5-Hydroxyme-thylcytosine expression is associated with poor
survival in cervical squamous cell carcinoma. Jpn J Clin Oncol.
46:427–434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Iyer LM, Tahiliani M, Rao A and Aravind L:
Prediction of novel families of enzymes involved in oxidative and
other complex modifications of bases in nucleic acids. Cell Cycle.
8:1698–1710. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sood S and Srinivasan R: Alterations in
gene promoter methylation and transcript expression induced by
cisplatin in comparison to 5-azacytidine in HeLa and SiHa cervical
cancer cell lines. Mol Cell Biochem. 404:181–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen CC, Lee KD, Pai MY, Chu PY, Hsu CC,
Chiu CC, Chen LT, Chang JY, Hsiao SH and Leu YW: Changes in DNA
methylation are associated with the development of drug resistance
in cervical cancer cells. Cancer Cell Int. 15:982015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Narayan G, Xie D, Ishdorj G, Scotto L,
Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A,
Arias-Pulido H and Murty VV: Epigenetic inactivation of TRAIL decoy
receptors at 8p12-21.3 commonly deleted region confers sensitivity
to Apo2L/trail-Cisplatin combination therapy in cervical cancer.
Genes Chromosomes Cancer. 55:177–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jascur T and Boland CR: Structure and
function of the components of the human DNA mismatch repair system.
Int J Cancer. 119:2030–2035. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Eto T, Zhao Y, Maruyama A, Miyashita K,
Yasui A, Nakao S, Taguchi K, Shimokawa M, Oda S and Saito T: Modal
variety of microsatellite instability in human endometrial
carcinomas. J Cancer Res Clin Oncol. 142:353–363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bilbao C, Lara PC, Ramírez R,
Henríquez-Hernández LA, Rodríguez G, Falcón O, León L, Perucho M,
Díaz-Chico BN and Díaz-Chico JC: Microsatellite instability
predicts clinical outcome in radiation-treated endometrioid
endometrial cancer. Int J Radiat Oncol Biol Phys. 76:9–13. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hampel H, Frankel W, Panescu J, Lockman J,
Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA,
et al: Screening for Lynch syndrome (hereditary nonpolyposis
colorectal cancer) among endometrial cancer patients. Cancer Res.
66:7810–7817. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Devor EJ, Schickling BM, Reyes HD, Warrier
A, Lindsay B, Goodheart MJ, Santillan DA and Leslie KK: Cullin-5, a
ubiquitin ligase scaffold protein, is significantly underexpressed
in endometrial adenocarcinomas and is a target of miR-182. Oncol
Rep. 35:2461–2465. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F,
Yan Y, Shi J and Hu Y: microRNA-30c negatively regulates
endometrial cancer cells by targeting metastasis-associated gene-1.
Oncol Reports. 27:807–812. 2012.
|
|
60
|
Boren T, Xiong Y, Hakam A, Wenham R, Apte
S, Wei Z, Kamath S, Chen DT, Dressman H and Lancaster JM: MicroRNAs
and their target messenger RNAs associated with endometrial
carcinogenesis. Gynecol Oncol. 110:206–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lee H, Park CS, Deftereos G, Morihara J,
Stern JE, Hawes SE, Swisher E, Kiviat NB and Feng Q: MicroRNA
expression in ovarian carcinoma and its correlation with
clinicopathological features. World J Surg Oncol. 10:1742012.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li S, Yang C, Zhai L, Zhang W, Yu J, Gu F,
Lang R, Fan Y, Gong M, Zhang X and Fu L: Deep sequencing reveals
small RNA characterization of invasive micropapillary carcinomas of
the breast. Breast Cancer Res Treat. 136:77–87. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Duenas-Gonzalez A, Medina-Franco JL,
Chavez-Blanco A, Dominguez-Gomez G and Fernández-de Gortari E:
Developmental DNA methyltransferase inhibitors in the treatment of
gynecologic cancers. Expert Opin Pharmacother. 17:323–338. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Song Y and Zhang C: Hydralazine inhibits
human cervical cancer cell growth in vitro in association with APC
demethylation and re-expression. Cancer Chemother Pharmacol.
63:605–613. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Tsuruta T, Kozaki K, Uesugi A, Furuta M,
Hirasawa A, Imoto I, Susumu N, Aoki D and Inazawa J: miR-152 is a
tumor suppressor microRNA that is silenced by DNA hypermethylation
in endometrial cancer. Cancer Res. 71:6450–6462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhao X, Zhu D, Lu C, Yan D, Li L and Chen
Z: MicroRNA-126 inhibits the migration and invasion of endometrial
cancer cells by targeting insulin receptor substrate 1. Oncol Lett.
11:1207–1212. 2016.PubMed/NCBI
|
|
68
|
Ren J, Zhang J, Cai H, Li Y, Zhang Y,
Zhang X, Zhao D, Li Z, Ma H, Wang J, et al: HDAC as a therapeutic
target for treatment of endometrial cancers. Curr Pharm Des.
20:1847–1856. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yi TZ, Li J, Han X, Guo J, Qu Q, Guo L,
Sun HD and Tan WH: DNMT inhibitors and HDAC inhibitors regulate
E-cadherin and bcl-2 expression in endometrial carcinoma in
vitro and in vivo. Chemotherapy. 58:19–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
